According to Tipranks, the biotech stocks that are trending, due to analyst coverage in the last few days, include Valeant Pharma (NYSE: VRX), Celgene (NASDAQ: CELG), and Sarepta Therapeutics (NASDAQ: SRPT). The complete list is in the table below:
Ticker Company Name Market Cap Recent # of Buys Recent # of Holds Recent # of Sells
JAZZ Jazz Pharmaceuticals $10,244,355,200 5 2 0
SRPT Sarepta Therapeutics $6,277,532,100 11 2 0
VRX Valeant Pharma $7,710,757,200 4 4 3
ENDP Endo International $1,409,837,200 2 5 0
MDGL Madrigal Pharmaceuticals Inc $3,910,684,200 7 0 0
MDT Medtronic $118,940,980,500 6 2 0
CELG Celgene $57,865,184,000 7 4 0
TEVA Teva Pharma $22,284,020,000 3 5 0
AGIO Agios Pharma $5,573,480,600 6 1 0
LOXO Loxo Oncology $5,611,038,900 8 0 0
BMRN BioMarin $16,237,987,900 7 0 0
ALGN Align Tech $26,695,165,000 7 0 0
GBT Global Blood Therapeutics $2,568,940,900 8 0 0
REGN Regeneron $33,097,393,700 3 3 1
ONCE Spark Therapeutics $2,997,540,100 9 1 0
MNK Mallinckrodt $1,410,920,000 1 5 1
Valeant is the most controversial among the analysts with three 'sell' calls against four buys, and four holds. The company’s main divisions, Bausch and Lomb and Salix, reported improving revenue in the last quarter. A higher staff count and a stabilization in R&D spend is contributing positively to results.
Analysts have an average downside PT of $19.82.
Teva Pharmaceuticals (NYSE: TEVA) earned the most "hold" calls. At three times the market cap of Valeant, Teva’s consolidation of its Actavis Generics unit will drive organic profit growth. Asset sales will par debt levels but Teva’s line of new drugs in the pipeline will eventually add to results three to five years down the road.
Regeneron (NASDAQ: REGN), which closed above $300/share last week, looks like a value play at a 15x forward P/E and a share price that is over 40% below its yearly high. The stock could make a run back up with 30% gains if the sentiment for the company brightens.
